116 related articles for article (PubMed ID: 31904566)
21. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
Dessy FJ; Giannini SL; Bougelet CA; Kemp TJ; David MP; Poncelet SM; Pinto LA; Wettendorff MA
Hum Vaccin; 2008; 4(6):425-34. PubMed ID: 18948732
[TBL] [Abstract][Full Text] [Related]
22. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial.
Pinto LA; Kemp TJ; Torres BN; Isaacs-Soriano K; Ingles D; Abrahamsen M; Pan Y; Lazcano-Ponce E; Salmeron J; Giuliano AR
J Infect Dis; 2016 Oct; 214(8):1276-83. PubMed ID: 27511896
[TBL] [Abstract][Full Text] [Related]
23. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
[TBL] [Abstract][Full Text] [Related]
24. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.
Nicol AF; Grinsztejn B; Friedman RK; Veloso VG; Cunha CB; Georg I; Pilotto JH; Moreira RI; Castro CA; Silver B; Viscidi RP
J Clin Virol; 2013 Jun; 57(2):147-51. PubMed ID: 23490398
[TBL] [Abstract][Full Text] [Related]
25. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
Kumakech E; Berggren V; Wabinga H; Lillsunde-Larsson G; Helenius G; Kaliff M; Karlsson M; Kirimunda S; Musubika C; Andersson S
PLoS One; 2016; 11(8):e0160099. PubMed ID: 27482705
[TBL] [Abstract][Full Text] [Related]
26. Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.
Marais DJ; Constant D; Allan B; Carrara H; Hoffman M; Shapiro S; Morroni C; Williamson AL
J Clin Microbiol; 2008 Feb; 46(2):732-9. PubMed ID: 18077644
[TBL] [Abstract][Full Text] [Related]
27. Determinants of seropositivity among HPV-16/18 DNA positive young women.
Porras C; Bennett C; Safaeian M; Coseo S; Rodríguez AC; González P; Hutchinson M; Jiménez S; Sherman ME; Wacholder S; Solomon D; van Doorn LJ; Bougelet C; Quint W; Schiffman M; Herrero R; Hildesheim A;
BMC Infect Dis; 2010 Aug; 10():238. PubMed ID: 20698998
[TBL] [Abstract][Full Text] [Related]
28. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 seroconversion promotes rapid changes in cervical human papillomavirus (HPV) prevalence and HPV-16 antibodies in female sex workers.
Marais DJ; Carrara H; Ramjee G; Kay P; Williamson AL
J Med Virol; 2009 Feb; 81(2):203-10. PubMed ID: 19107974
[TBL] [Abstract][Full Text] [Related]
30. Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys.
Vaccarella S; Franceschi S; Clifford GM; Touzé A; Hsu CC; de Sanjosé S; Pham TH; Nguyen TH; Matos E; Shin HR; Sukvirach S; Thomas JO; Boursaghin L; Gaitan J; Snijders PJ; Meijer CJ; Muñoz N; Herrero R; Coursaget P;
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2379-88. PubMed ID: 20826835
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.
Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR
PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629
[TBL] [Abstract][Full Text] [Related]
32. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
[TBL] [Abstract][Full Text] [Related]
33. AIDS Malignancy Consortium 054: Safety and Immunogenicity of the Quadrivalent Vaccine in Indian Women Living With HIV.
Palefsky JM; Poongulali S; Lensing S; Lee J; Da Costa M; Chein A; Beulah F; Murugavel KG; Kumarasamy N
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):875-881. PubMed ID: 33587509
[TBL] [Abstract][Full Text] [Related]
34. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England.
Mesher D; Soldan K; Howell-Jones R; Panwar K; Manyenga P; Jit M; Beddows S; Gill ON
Vaccine; 2013 Dec; 32(1):26-32. PubMed ID: 24211166
[TBL] [Abstract][Full Text] [Related]
35. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
36. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
Brown D; Müller M; Sehr P; Pawlita M; Seitz H; Rubio I; Antonello J; Radley D; Roberts C; Saah A
Vaccine; 2014 Oct; 32(44):5880-7. PubMed ID: 25148777
[TBL] [Abstract][Full Text] [Related]
37. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection.
Simen-Kapeu A; Kataja V; Yliskoski M; Syrjänen K; Dillner J; Koskela P; Paavonen J; Lehtinen M
Scand J Infect Dis; 2008; 40(9):745-51. PubMed ID: 19086247
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
39. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and genotype distribution of human papillomavirus among women from Henan, China.
Wang XC; Sun LQ; Ma L; Li HX; Wang XL; Wang X; Yun T; Meng NL; Lv DL
Asian Pac J Cancer Prev; 2014; 15(17):7333-6. PubMed ID: 25227838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
